Please check your internet connection and try again.
# Tab Voihep
## Overview
Tab Voihep is a brand name for **benzoic acid and sodium benzoate** oral solution. It is a uricosuric agent used to treat hyperuricemia associated with certain conditions.
## Primary Indications
* Management of hyperuricemia associated with **antineoplastic therapy** (tumor lysis syndrome).
## Adult Dosing
* **Prophylaxis for Tumor Lysis Syndrome:** 1 gram/kg/day orally, divided into 3-4 doses.
* **Maximum Dose:** 8 grams/day.
* Dosing should be initiated 24-48 hours prior to chemotherapy.
## Pediatric Dosing
* Dosing in pediatric patients should be based on body surface area (BSA) or body weight and should be individualized. Consult specific pediatric oncology protocols.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Significant renal impairment may require dose reduction or avoidance.
* **Hepatic Impairment:** Use with caution.
## Contraindications
* Hypersensitivity to benzoic acid or sodium benzoate.
* Severe renal impairment (CrCl < 30 mL/min).
* Concurrent use with drugs that are secreted by active tubular secretion and compete for elimination (e.g., salicylates, probenecid, NSAIDs) - may lead to paradoxical increase in serum uric acid.
## Adverse Effects
* Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain.
* Electrolyte disturbances: Hyperkalemia, hypomagnesemia, hypophosphatemia.
* Renal: Renal tubular damage, crystalluria (if urine pH is not adequately maintained).
* Metabolic: Metabolic acidosis.
## Key Drug Interactions
* **Salicylates (including NSAIDs):** Concomitant use can inhibit the uricosuric effect and potentially lead to paradoxical hyperuricemia. Avoid concurrent use.
* **Probenecid:** Similar to salicylates, may compete for elimination and reduce efficacy.
* **Antacids:** May alter urine pH, potentially affecting drug excretion.
## Monitoring
* **Urine pH:** Monitor frequently (every 4-6 hours) and maintain urine pH > 6.0 with alkali therapy (e.g., sodium bicarbonate, acetazolamide) to prevent crystalluria and renal damage.
* **Serum Uric Acid:** Monitor to assess efficacy.
* **Electrolytes:** Monitor potassium, magnesium, and phosphate levels, especially in patients receiving other agents for tumor lysis syndrome management.
* **Renal Function:** Monitor BUN and creatinine.
## Clinical Pearls
* Adequate hydration is crucial. Patients should receive intravenous fluids to ensure sufficient urine output.
* Maintaining urine pH > 6.0 is paramount to prevent uric acid crystal formation in the renal tubules.
* This medication is typically used for short-term prophylaxis during chemotherapy-induced tumor lysis.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions. This information does not replace professional medical advice.
